Skip to content
Bored Studies
RecruitingPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Eli Lilly and Company · NCT07321886

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
1980
US sites recruiting
41
Study start
February 6, 2026
Record last updated
September 22, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.

Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.

Being studied: Eloralintide; Placebo

Conditions: Obesity; Overweight

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Have Body Mass Index (BMI) at screening of the following:
  • 30 kilogram per square meter (kg/m2) OR
  • 27 kg/m2 with at least one of the following weight-related health conditions at screening:
  • high blood pressure
  • dyslipidemia
  • obstructive sleep apnea, or
  • heart disease
  • Have a stable body weight (\<5% body weight change) for 90 days prior to screening.
  • Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight

Exclusion Criteria

  • Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
  • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
  • Have type 1 diabetes or type 2 diabetes
  • Have had within 90 days prior to screening:
  • heart attack
  • stroke
  • coronary artery revascularization
  • unstable angina, or
  • hospitalization due to congestive heart failure
  • Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
  • Have taken medications or alternative remedies intended for weight loss within 90 days of screening

Recruiting US locations

  • MFA Clinical Research

    Tuscaloosa, AL 35405

    Site contact: 205-331-4963

  • Headlands Research - Scottsdale

    Scottsdale, AZ 85260

    Site contact: 480-725-8708

  • Neighborhood Healthcare Institute of Health

    Escondido, CA 92025

    Site contact: 760-737-6984

  • Ark Clinical Research - Fountain Valley

    Fountain Valley, CA 92708

    Site contact: 714-988-2021

  • Desert Oasis Healthcare Medical Group

    Palm Springs, CA 92262

    Site contact: 760-320-9505

  • Peninsula Research Associates

    Rolling Hills Estates, CA 90274

    Site contact: 310-265-1623

  • Care Access - Sacramento

    Sacramento, CA 95831

    Site contact: 925-734-2331

  • Southern California Clinical Research

    Santa Ana, CA 92701

    Site contact: 714-474-2173

  • University Clinical Investigators, Inc.

    Tustin, CA 92780

    Site contact: 714-734-7944

  • Chase Medical Research, LLC

    Waterbury, CT 06708

    Site contact: 203-437-6856

  • JEM Research Institute

    Atlantis, FL 33462

    Site contact: 561-968-2933

  • BioMed Research & Medical Center

    Miami, FL 33156

    Site contact: 786-238-7110

  • Adult Medicine of Lake County, Inc.

    Mt. Dora, FL 32757

    Site contact: 352-383-8222

  • American Research Centers of Florida

    Pembroke Pines, FL 33027

    Site contact: 954-237-3799

  • AHF Pensacola

    Pensacola, FL 32503

    Site contact: 850-476-3131 x53026

  • IMA Clinical Research St. Petersburg

    St. Petersburg, FL 33704

    Site contact: 727-521-9137

  • Teak Research Consults - Dunwoody

    Dunwoody, GA 30338

    Site contact: 470-403-4755

  • Teak Research Consults

    Lawrenceville, GA 30043

    Site contact: Kamar Alabi

  • Clinical Research Atlanta

    Stockbridge, GA 30281

    Site contact: 770-507-6867

  • East-West Medical Research Institute

    Honolulu, HI 96814

    Site contact: 808-531-6886

  • Iowa Diabetes and Endocrinology Research Center

    West Des Moines, IA 50266

    Site contact: Amy Keller

  • Cotton O'Neil Clinical Research Center

    Topeka, KS 66606

    Site contact: 785-354-9591

  • Care Access - Lake Charles (Bayou Pines)

    Lake Charles, LA 70601

    Site contact: 337-602-6642

  • MedStar Good Samaritan Hospital

    Baltimore, MD 21239

    Site contact: 443-444-6275

  • MedStar Health Research Institute (MedStar Physician Based Research Network)

    Hyattsville, MD 20782

    Site contact: 443-444-5663

  • Care Access - Quincy

    Quincy, MA 02169

    Site contact: 877-791-0656

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

    Troy, MI 48098

    Site contact: 248-312-0025

  • AMR Clinical

    Las Vegas, NV 89119

    Site contact: 702-597-9825

  • IMA Clinical Research Warren

    Warren Township, NJ 07059

    Site contact: Nancy Phillips

  • Albuquerque Clinical Trials, Inc.

    Albuquerque, NM 87102

    Site contact: 505-224-7407

  • Rochester Clinical Research, LLC

    Rochester, NY 14609

    Site contact: 585-288-0890

  • Monroe Biomedical Research

    Monroe, NC 28112

    Site contact: 704-283-7359

  • Preferred Primary Care Physicians

    Uniontown, PA 15401

    Site contact: 724-912-0033

  • Tribe Clinical Research, LLC

    Greenville, SC 29607

    Site contact: 864-334-0141

  • Accellacare - Mt Pleasant

    Mt. Pleasant, SC 29464

    Site contact: 843-849-1880

  • AMR Clinical

    Nashville, TN 37203

    Site contact: 630-491-1900

  • The University of Texas Health Science Center at Houston

    Bellaire, TX 77401

    Site contact: 713-486-1350

  • Velocity Clinical Research, Dallas

    Dallas, TX 75230

    Site contact: Dan Lender

  • UT Southwestern Medical Center

    Dallas, TX 75390-9302

    Site contact: Amy Shah

  • IMA Clinical Research San Antonio

    San Antonio, TX 78229

    Site contact: 210-692-7157

  • AMR Clinical

    Norfolk, VA 23502

    Site contact: 757-627-7446

Study contacts (from the official record)

  • Trial question or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
  • Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
All weight loss studies in Alabama →
A Study of Eloralintide (LY3841136) in Participants With Obesity,… (NCT07321886) | Bored Studies